Association of polypharmacy and burden of comorbidities on COVID-19 adverse outcomes in people with type 1 or type 2 diabetes

JK Gupta, R Ravindrarajah, G Tilston, W Ollier, DM Ashcroft, AH Heald
doi: https://doi.org/10.1101/2023.08.12.23294016

Article Information

doi 
https://doi.org/10.1101/2023.08.12.23294016
History 
  • August 19, 2024.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. JK Gupta1,
  2. R Ravindrarajah1,
  3. G Tilston1,
  4. W Ollier2,
  5. DM Ashcroft3,4 and
  6. AH Heald5,6,*
  1. 1Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
  2. 2Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK
  3. 3Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
  4. 4NIHR Greater Manchester Patient Safety Research Collaboration (PSRC), University of Manchester, UK
  5. 5Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK
  6. 6Faculty of Biology, Medicine and Health, University of Manchester, UK
  1. ↵*Corresponding author: Adrian.Heald{at}nca.nhs.uk
Back to top
Posted August 19, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Association of polypharmacy and burden of comorbidities on COVID-19 adverse outcomes in people with type 1 or type 2 diabetes
JK Gupta, R Ravindrarajah, G Tilston, W Ollier, DM Ashcroft, AH Heald
medRxiv 2023.08.12.23294016; doi: https://doi.org/10.1101/2023.08.12.23294016
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area